USE OF CANNABIDIOL IN PATIENTS WITH REFRACTORY EPILEPSY: AN INTEGRATIVE REVIEW OF CLINICAL AND THERAPEUTIC EVIDENCE
Authors:
- Álvaro Dias de Alkmin FilhoÁFÁlvaro Dias de Alkmin Filho
- David José Conceição VilaDVDavid José Conceição Vila
- Ramon de Mendonça CorreiaRCRamon de Mendonça Correia
- Marcela Marinho de OliveiraMOMarcela Marinho de Oliveira
- Lívia Ayres Mendes KhairLKLívia Ayres Mendes Khair
- Thallía Vitória Oliveira MotaTMThallía Vitória Oliveira Mota
- Rafael Costa dos SantosRSRafael Costa dos Santos
- Ednei Luiz França CajáECEdnei Luiz França Cajá
- Bruna Lopes AlegrioBABruna Lopes Alegrio
- Joel Mariano Gomes PereiraJPJoel Mariano Gomes Pereira
- Nathália Déo GasparottoNGNathália Déo Gasparotto
- Mateus Giovani SennaMSMateus Giovani Senna
Open Access
- 3 October 2025
- book chapter
- Published by Seven Events
- p. 165-183
Abstract
This study presents an integrative review of the clinical and therapeutic evidence available on the use of cannabidiol (CBD) in patients with refractory epilepsy. This condition is characterized by resistance to conventional antiepileptic treatments, making seizure control a significant challenge for both patients and healthcare professionals. CBD, a non-psychoactive compound derived from Cannabis sativa, has shown promising potential in managing epileptic seizures, particularly in syndromes such as Dravet and Lennox-Gastaut. Based on the analysis of recent clinical studies, benefits have been observed regarding seizure frequency reduction, improved quality of life, and an acceptable safety profile when used under medical supervision. However, further studies are needed to standardize dosages and assess long-term effects. This review also highlights the importance of developing public policies that regulate access to treatment, ensuring safety and equity in the provision of this therapy.Keywords
This publication has 32 references indexed in Scilit:
- Second-line cannabis therapy in patients with epilepsyClinical Neurology and Neurosurgery, 2023
- Antiseizure Medications for Adults With EpilepsyJAMA, 2022
- Epilepsy as a dynamical system, a most needed paradigm shift in epileptologyEpilepsy & Behavior, 2021
- Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut SyndromeCNS Drugs, 2021
- Guidelines for the diagnosis and treatment of acute encephalopathy in childhoodBrain and Development, 2021
- Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic EncephalopathyPediatric Drugs, 2019
- Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the USCNS Drugs, 2018
- Cannabis for the Treatment of Epilepsy: an UpdateCurrent Neurology and Neuroscience Reports, 2018
- Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North AmericaEuropean Journal of Internal Medicine, 2018
- Influence of seizures on early development in tuberous sclerosis complexEpilepsy & Behavior, 2017